Multiple Factors Drive Ongoing Rise In Liver Cancer- The U.S. incidence of hepatocellular carcinoma continues to rise, and will likely remain on that trajectory for at least a decade, due to the epidemics of obesity and type 2 diabetes, as well as infections with hepatitis B and C.
Newsletter:
GI & HEPATOLOGY NEWS July 2012 Issue
Download PDF
Multiple Factors Drive Ongoing Rise
In Liver Cancer
BY MITCHEL L. ZOLER
Elsevier Global Medical News
SAN DIEGO – The U.S. incidence
of hepatocellular carcinoma
continues to rise, and
will likely remain on that trajectory
for at least a decade,
due to the epidemics of obesity
and type 2 diabetes, as
well as infections with hepatitis
B and C.
“I think rates will increase for
another 10-20 years,” predicted
Dr. Alita Mishra, one of two researchers
who reported results
on this topic at the annual Digestive
Disease Week. The two
investigators conducted independent
studies that revealed
increased rates of hepatocellular
carcinoma (HCC) in
the United States during the
2000s.
Greater vigilance is therefore
needed to spot incident
cases early, Dr. Mishra said in
an interview. While patients
with hepatitis C who develop
cirrhosis usually undergo routine
routine,
serial ultrasound screening
for liver lesions, regular surveillance
occurs less often in
patients with cirrhosis related
to hepatitis B, or those with cirrhosis
due to nonalcoholic fatty
liver disease (NAFLD) that is
secondary to obesity or type 2
diabetes.
“Patients with cirrhosis
should undergo regular HCC
screening regardless of the underlying
cause,” Dr. Mishra
said.
One analysis, based on data
collected by the Surveillance,
Epidemiology and End Results
(SEER) registry of the
National Cancer Institute,
showed that U.S. HCC rates
rose threefold from 1975 to
2007, including a 33% rise during
1998-2007, Jessica A. Davila,
Ph.D. reported at the
meeting.
The second analysis, using
data from the Nationwide Inpatient
Sample (NIS), showedthat the number of patients hospitalized
with HCC per 100,000
hospital discharges jumped from
148 in 2005 to 213 in 2009, said Dr.
Mishra, a hospitalist at Inova Fairfax
(Va.) Hospital.
“HCC is rising because of hepatitis
C viral infection, especially in
people born during 1945-1965,” Dr.
Mishra said in an interview. Many
of these people don’t know they are
infected, and it usually takes decades
for them to develop HCC.
The second big factor is the rising
prevalences of obesity and type 2
diabetes.
“Hepatitis C infections are now
falling, so perhaps the rise in new
HCC cases will eventually peak,
but not if other factors like obesity
and type 2 diabetes continue to
push it up,” she said.
“What is driving a lot of the increase
is hepatitis C virus, and the
high prevalence of hepatitis B
virus in foreign-born Asians,” said
Dr. Davila, a clinical epidemiologist
at the Houston VA Medical
Center and Baylor College of
Medicine in Houston.
“A lot also has to do with obesity
and type 2 diabetes and their association
with nonalcoholic fatty
liver disease, especially in middleaged,
Hispanic women. I think
we’ll see the greatest increase in
HCC in women during the next 2
decades,”
Dr. Davila said. She also
predicted increasing numbers of
hepatitis C virus–driven HCC cases
in the short term. “As the [infected]
cohort ages, increasing
numbers will develop advanced fibrosis
and eventually HCC,” she
said.
Dr. Davila’s study used data from
SEER, which the National Cancer
Institute began in 1973 to collect
data on cancer cases from about
14% of the U.S. population in selectedstates and metropolitan areas.
During 1975-2007, SEER tallied
a total of 21,472 HCC cases, about
80% of which occurred in people
aged 50-79 years; roughly 75% of
cases were in men.
HCC incidence rose from 1.6
cases per 100,000 people during
1975-1977 to 4.8 per 100,000 in
2005-2007. Roughly a tripling of
cases during the three decades
occurred in both sexes. The
greatest increase occurred among
people aged 50-59 years, with a
nearly fivefold jump, from 2.6 to
12.6 per 100,000 between 1975-
1977 and 2005-2007. The smallest
rise was 2.4-fold among people
aged 70-79.
By 2005-2007, the highest rate
per 100,000 was among Asians, at
10.3, followed by 8.2 in Hispanics,
7.5 in blacks, and 3.7 in whites
(see graphic).
Dr. Mishra’s study used data collected
in NIS by the Agency for
Healthcare Research and Quality
from about 1,000 hospitals in 44
states. The number of patients
hospitalized with HCC
(not confined to incident
cases) rose from 9,537 in
2005 to 13,689 in 2009.
During the 5-year period,
in-hospital mortality of
HCC patients dropped
from 120 per 1,000 cases in
2005 to 95 per 1,000 cases in
2009, and the median
length of stay fell by about0.5 days.
There was an
uptick in the percentage of
cases having “major” or
“extreme” illness, from
52% in 2005 to 63% in 2009,
and the average number of
comorbidities also rose
steadily during the 5 years
studied.
Dr. Davila and Dr. Mishra
reported having no conflicts
of interest. ■
http://www.gastro.org/journals-publications/gi-hepatology-news/GIHEP_July_2012_LoRes_AGA_Nxtbooks.pdf
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment